JP2025003964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025003964A5 JP2025003964A5 JP2024155019A JP2024155019A JP2025003964A5 JP 2025003964 A5 JP2025003964 A5 JP 2025003964A5 JP 2024155019 A JP2024155019 A JP 2024155019A JP 2024155019 A JP2024155019 A JP 2024155019A JP 2025003964 A5 JP2025003964 A5 JP 2025003964A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306173.8 | 2018-09-06 | ||
| EP18306173 | 2018-09-06 | ||
| PCT/EP2019/073883 WO2020049169A1 (en) | 2018-09-06 | 2019-09-06 | Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine |
| JP2021512759A JP7633930B2 (ja) | 2018-09-06 | 2019-09-06 | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512759A Division JP7633930B2 (ja) | 2018-09-06 | 2019-09-06 | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025003964A JP2025003964A (ja) | 2025-01-14 |
| JP2025003964A5 true JP2025003964A5 (enExample) | 2025-03-18 |
Family
ID=63683819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512759A Active JP7633930B2 (ja) | 2018-09-06 | 2019-09-06 | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 |
| JP2024155019A Pending JP2025003964A (ja) | 2018-09-06 | 2024-09-09 | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512759A Active JP7633930B2 (ja) | 2018-09-06 | 2019-09-06 | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210330774A1 (enExample) |
| EP (1) | EP3846839A1 (enExample) |
| JP (2) | JP7633930B2 (enExample) |
| KR (1) | KR20210055725A (enExample) |
| CN (1) | CN112867502A (enExample) |
| AU (1) | AU2019334676B2 (enExample) |
| BR (1) | BR112021004244A2 (enExample) |
| CA (1) | CA3111663A1 (enExample) |
| IL (1) | IL281253B2 (enExample) |
| MX (1) | MX2021002519A (enExample) |
| SG (1) | SG11202102290RA (enExample) |
| WO (1) | WO2020049169A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000006973A1 (it) * | 2020-04-02 | 2021-10-02 | Istituto Naz Tumori Irccs Fondazione G Pascale | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro |
| US11791123B2 (en) | 2021-04-29 | 2023-10-17 | Electronics And Telecommunications Research Institute | X-ray tube |
| US20250147046A1 (en) | 2022-01-25 | 2025-05-08 | Ervimmune | New method for identifying herv-derived epitopes |
| WO2023242343A1 (en) | 2022-06-15 | 2023-12-21 | Immunoscape Pte. Ltd. | Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4950645A (en) | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| JP2004535765A (ja) * | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | 前立腺癌においてアップレギュレートされた内因性レトロウイルス |
| WO2003106634A2 (en) * | 2002-06-13 | 2003-12-24 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
| JP2005535308A (ja) | 2002-06-13 | 2005-11-24 | カイロン コーポレイション | Ｈｍｌ−２ポリペプチド発現用ベクター |
| WO2006103562A2 (en) * | 2005-03-30 | 2006-10-05 | Centre National De La Recherche Scientifique (Cnrs) | Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| SG173997A1 (en) | 2006-07-21 | 2011-09-29 | Univ California | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
-
2019
- 2019-09-06 US US17/273,677 patent/US20210330774A1/en active Pending
- 2019-09-06 SG SG11202102290RA patent/SG11202102290RA/en unknown
- 2019-09-06 CA CA3111663A patent/CA3111663A1/en active Pending
- 2019-09-06 JP JP2021512759A patent/JP7633930B2/ja active Active
- 2019-09-06 CN CN201980066213.5A patent/CN112867502A/zh active Pending
- 2019-09-06 KR KR1020217009691A patent/KR20210055725A/ko not_active Ceased
- 2019-09-06 BR BR112021004244-0A patent/BR112021004244A2/pt unknown
- 2019-09-06 MX MX2021002519A patent/MX2021002519A/es unknown
- 2019-09-06 IL IL281253A patent/IL281253B2/en unknown
- 2019-09-06 WO PCT/EP2019/073883 patent/WO2020049169A1/en not_active Ceased
- 2019-09-06 EP EP19762429.9A patent/EP3846839A1/en active Pending
- 2019-09-06 AU AU2019334676A patent/AU2019334676B2/en active Active
-
2024
- 2024-09-09 JP JP2024155019A patent/JP2025003964A/ja active Pending